WA
TCON

Waverly Advisors’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Waverly Advisors’s Portfolio TCON Stock Details TCON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-107
Closed -$44K – 200
2018
Q3 		$44K Hold
107
– – 0.01% 191
2018
Q2 		$58K Hold
107
– – 0.01% 185
2018
Q1 		$49K Hold
107
– – 0.01% 172
2017
Q4 		$71K Buy
+107
New +$64.6K 0.01% 242

Other funds holding TCON

PCM
Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
TI
Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Waverly Advisors's TCON Position: Q4 2018 in Review

Waverly Advisors sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q4 2018, closing a stake of 107 shares — an estimated $44K sold.

Waverly Advisors first reported a position in TCON in Q4 2017 and held it in 4 quarters. The position peaked at $71K in Q4 2017. 27 funds tracked by Wall St. Rank hold TCON as of Q4 2018.

  • Waverly Advisors reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Waverly Advisors sold 107 TRACON Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $44K.
  • Waverly Advisors first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q4 2017 and held it in 4 quarters.
  • Waverly Advisors's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $71K in Q4 2017.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Waverly Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.